AUTHOR=Cai Yi-Jing , Dong Jia-Jia , Chen Rui-Cong , Xiao Qian-Qian , Li Xu-Mei , Chen De-Yuan , Cai Chao , Lin Xiu-Li , Shi Ke-Qing , Lu Ming-Qin
TITLE=Serum ammonia variation predicts mortality in patients with hepatitis B virus-related acute-on-chronic liver failure
JOURNAL=Frontiers in Microbiology
VOLUME=14
YEAR=2023
URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1282106
DOI=10.3389/fmicb.2023.1282106
ISSN=1664-302X
ABSTRACT=BackgroundHyperammonemia is critical to the development of hepatic encephalopathy (HE) and is associated with mortality in end-stage liver disease. This study investigated the clinical value of ammonia variation in hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) patients.
MethodsA total of 276 patients with HBV-ACLF were retrospectively recruited. Patients' ammonia levels were serially documented. Baseline ammonia, Peak ammonia (highest level), and Trough ammonia (lowest level) were particularly corrected to the upper limit of normal (AMM-ULN). The primary endpoint was 28-day mortality.
ResultsThe 28-day, 3-month, and 12-month mortality rates were 19.2, 25.7, and 28.2%, respectively. A total of 51 (18.4%) patients had overt HE (grade 2/3/4). Peak AMM-ULN was significantly higher in patients with overt HE and non-survivors compared with their counterparts (P < 0.001). Following adjustment for significant confounders, high Peak AMM-ULN was an independent predictor of overt HE (hazard ratio, 1.031, P < 0.001) and 28-day mortality (hazard ratio, 1.026, P < 0.001). The cut-off of Peak AMM-ULN was 1.8, determined by using the X-tile. Patients with Peak AMM-ULN appearing on days 1–3 after admission had a higher proportion of overt HE and mortality compared to other groups. Patients with decreased ammonia levels within 7 days had better clinical outcomes than those with increased ammonia.
ConclusionSerum Peak ammonia was independently associated with overt HE and mortality in HBV-ACLF patients. Serial serum ammonia may have prognostic value.